CryoCath Introduces Arctic Front in Italy, Belgium and Spain
    Toronto Stock Exchange Symbol: CYT

    MONTREAL, June 27 /CNW/ - CryoCath(R) Technologies Inc., the global
leader in cryotherapy products to treat cardiac arrhythmias, today announced
the introduction of Arctic Front(R) in Italy, Belgium and Spain. Arctic Front,
the Company's lead product for the treatment of paroxysmal atrial fibrillation
(PAF), is a unique cryoablation balloon catheter that allows physicians to
safely and effectively isolate all four pulmonary veins for the treatment of
    "The introduction of Arctic Front in Italy, Belgium and Spain provides us
with an exciting opportunity to deliver the benefits of our breakthrough
therapy to a larger patient population and drive one of our key corporate
goals of explosive and profitable revenue growth in Europe," said Jan
Keltjens, President and CEO of CryoCath. "As was the case in Australia and
Hong Kong, the European medical community has demonstrated great confidence in
Arctic Front based on its growing body of clinical evidence. By expanding our
already strong presence in Europe, we are continuing to drive the adoption of
our Arctic Front system worldwide."
    Prof. Dr. Claudio Tondo, Chief of the Cardiology Division and Director of
the Cardiac Arrhythmia and Heart Failure Research Institute at the San
Camillo-Forlanini Hospital in Rome, Italy performed the first procedures with
Arctic Front in Italy on June 9, 2008. Dr. Tondo will provide leadership for
the program in Italy, the second largest electrophysiology market in
continental Europe.
    "Arctic Front represents a step forward in the ablative strategies for
atrial fibrillation. The cryoballoon from CryoCath offers a safe and effective
approach favoring a substantial reduction of x-ray exposure time and, without
the need to carry out a double transseptal puncture," said Dr. Tondo. "The
cryo technology represents an effective alternative to radiofrequency energy
for safety reasons, prompting the extension of the ablative treatment to a
larger population of patients suffering from paroxysmal atrial fibrillation.
We are looking forward to a strong contribution towards expanding the use of
the cryo technology in the ablation of atrial fibrillation."
    The first Arctic Front procedures in Belgium were performed in May 2008
by Prof. Dr. Pedro Brugada, Head of the Heart Rhythm Management Centre, UZ
Brussel - Vrije Universiteit Brussel and Dr. Gian Battista Chierchia, Director
Atrial Fibrillation and Pacing Program. Drs. Brugada and Chierchia have
treated four patients in Brussels to date.
    "We see great promise in the procedural simplicity of the Arctic Front
System. The cryoballoon's innovative shape facilitates anatomical placement in
the atrium at the ostium of the targeted pulmonary vein," said Dr. Brugada.
"By its very design, the Arctic Front catheter simplifies the ablation of
pulmonary veins and may reduce procedural time in the treatment of atrial
fibrillation, in turn offering greater comfort for the patient and operator
    Prof. Dr. Julian Villacastin and his team at Hospital Clinico San Carlos
in Madrid, Spain have treated two patients since first using Arctic Front on
June 24, 2008. The patients treated to date have had successful outcomes and
no safety concerns have been reported. "We were very pleased with the ease of
use afforded by the cryoballoon, its simplicity and the success with our first
patients. We were particularly impressed with the spontaneous termination of
the patient's atrial fibrillation during the cryoablation and return of sinus
rhythm," said, Dr. Villacastin.

    About Arctic Front

    Arctic Front is a minimally invasive cryo-balloon catheter designed
specifically to treat paroxysmal Atrial Fibrillation. This bi-directional,
double balloon catheter enables physicians to rapidly isolate all four
pulmonary veins for the treatment of AFib. More than 2,600 patients have been
treated in more than 45 centres across Europe.

    About CryoCath

    CryoCath - - is a medical technology company that leads
the world in cryotherapy products to treat cardiac arrhythmias. With a
priority focus on providing physicians with a complete solution of catheter
products to treat cardiac arrhythmias, CryoCath has multiple products approved
in the U.S., across Europe and several ROW countries. The Company is
developing additional products to expand its pipeline of products to treat
cardiac arrhythmias.

    This press release includes "forward looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, currency, technological, competitive and other important
factors that could cause actual results to differ materially from those
anticipated in the forward looking statements, see CryoCath's annual report
available at under the heading Risks and Uncertainties in the
Management's Discussion and Analysis section.

    %SEDAR: 00015053E

For further information:

For further information: visit our website at, or
contact Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890